Rationale: Hepatectomy and adjuvant chemotherapy after resection of colorectal liver
metastases (CRLM) may improve survival, however, patients which may benefit cannot …

Background The surgical resection of colorectal cancer with liver metastases (CLM) has
proven to be the most important modality for long-term survival, while effective biomarkers …

Background Recurrence rates after resection of colorectal cancer liver metastases (CRLM)
are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is …

Background In patients with resectable colorectal liver metastases (CRLM), the role of pre-
and postoperative systemic therapy continues to be debated. Previous studies have shown …

Objective: To evaluate the association of perioperative ctDNA dynamics on outcomes after
hepatectomy for CLM. Summary Background Data: Prognostication is imprecise for patients …

Background The optimal perioperative management of patients who undergo hepatectomy
for resectable colorectal liver metastases (CRLM) remains unclear due to the lack of reliable …

Background Liver resection can be curative for well-selected metastatic colorectal cancer
(CRC) patients. Circulating tumor DNA (ctDNA) has shown promise as a biomarker for tumor …

Background For patients with colorectal liver metastases (CRLM) who receive neoadjuvant
therapy (NAT), reliable indicators that can early and accurately predict treatment response …

The recurrence rate of colorectal liver metastases (CRLM) patients treated with curative
intent is above 50%. Standard of care surveillance includes intensive computed …

PURPOSE Prognostic tools to estimate the risk of relapse for patients with liver-limited
metastatic colorectal cancer (LL-mCRC) undergoing resection with curative intent are …